Compare FLL & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLL | PMVP |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5M | 76.8M |
| IPO Year | 2014 | 2020 |
| Metric | FLL | PMVP |
|---|---|---|
| Price | $2.57 | $1.40 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 125.8K | ★ 398.3K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $302,376,000.00 | N/A |
| Revenue This Year | $7.54 | N/A |
| Revenue Next Year | $6.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.53 | N/A |
| 52 Week Low | $2.02 | $0.83 |
| 52 Week High | $4.95 | $1.88 |
| Indicator | FLL | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 50.54 |
| Support Level | $2.33 | $1.37 |
| Resistance Level | $2.74 | $1.51 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 42.39 | 27.27 |
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins. Geographically, it operates in United States.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.